Digostics, the UK-based health tech company behind the world’s first oral glucose intolerance test (OGTT) that can be done at home instead of a clinic or hospital, has announced it has surpassed £500,000 in funding on the Crowdcube equity crowdfunding platform, with more than 100 investors backing the company’s mission to revolutionise diabetes detection and monitoring.
GTT@home is an accurate home-use OGTT test kit developed by Digostics that uses finger-prick blood samples to measure how well the body processes glucose. The test is as accurate as lab-based OGTTs when used in adults with glucose intolerance, type 2 diabetes, or in pregnant women to diagnose gestational diabetes.
The raise builds on Digostics’ momentum across the UK and internationally, where GTT@home is already CE-marked, and approved for use in other markets. The digital platform has already delivered over 5,000 NHS tests and is being adopted by multiple NHS Trusts for gestational diabetes screening in pregnancy. The company is also driving early international interest with operations in the UAE and Singapore.
“Reaching the £500,000 threshold is an exciting moment, one that reflects investor belief in our mission to make diabetes screening simpler, earlier, and more accessible,” said James Jackson, CEO and Founder of Digostics. “With healthcare systems under increasing pressure, innovations like GTT@home can reduce clinical burden while improving patient experience and outcomes.”
About Digostics
Digostics is transforming diabetes care with GTT@home, the world's first at-home oral glucose tolerance test (OGTT). The CE-marked digital platform delivers home-based diabetes screening, supporting earlier detection and relieving healthcare system pressures. For more information, visit www.digostics.com.
